The firm plans to study the PI3K/AKT/mTOR inhibitor paxalisib in combination with Merck's Keytruda in microsatellite stable and proficient mismatch repair colorectal cancer.

New products for the week of Aug. 31, 2026: BillionToOne, Mirxes, OGT, and Eclipse Bioinnovations.

NEW YORK – New research suggests that molecular aging can vary considerably between individuals depending on their genetics and environmental exposures as well as the season and their circadian rhythm ...

The Fitrapid test is a noninvasive at-home kit designed to detect fecal occult blood, an early warning sign of lower gastrointestinal tract diseases.

The partners will create a secure, Rush-hosted clinical analytics platform to enable Rush researchers to analyze deidentified, longitudinal, and multimodal clinical data.

The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

The bank gave CareDx a price target of $65 per share and BillionToOne of $120 per share,  noting their strong positions in non-oncology markets and recent moves into cancer testing.

AstraZeneca will also share data with regulators from a Phase III study of Tagrisso and Orapthys in lung cancer.

The firm expects to file a biologics license application in the US for OCU410 in 2028 based on data from this Phase III program.

The Dow Jones Industrial Average rose 1 percent month over month, the Nasdaq rose 4 percent, and the Nasdaq Biotech Index rose 10 percent.